ArticleCureus2024
Rasburicase Plus Methotrexate Combination Therapy in a Case of Tophaceous, Difficult-to-Treat Gout.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in the management of gout: From current strategies to emerging therapies.The Journal of international medical research · 2026Review
- Advances in drug delivery systems for the management of gout and hyperuricemia.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout is a disease caused by the deposit of monosodium urate (MSU) crystals that produce joint inflammation and subcutaneous nodules (tophi). The treatment of gout aims to reduce serum uric acid (sUA) levels by administering urate-lowering therapies (ULT) such as xanthine oxidase inhibitors (XOI: allopurinol, febuxostat) or uricosurics (e.g., benzbromarone). However, some patients with tophaceous, difficult-to-treat (D2T) gout may not respond to or have poor tolerance of or contraindications to conventional treatment. Uricases such as pegloticase (PEG; polyethylene glycol-conjugated mammalian recombinant uricase), which degrades UA to allantoin (more soluble in urine), have emerged as a therapeutic alternative for such patients. The concomitant use of methotrexate (MTX) improves the efficacy and tolerance of intravenous PEG by reducing immunogenicity secondary to the formation of anti-PEG antibodies. However, this uricase is not marketed in Europe. Rasburicase, which is indicated for the treatment and prophylaxis of acute hyperuricemia resulting from tumor lysis syndrome in patients undergoing chemotherapy for hematologic malignancies, has been used off-label with some success in tophaceous gout. However, as with PEG, it is occasionally associated with potentially serious infusion reactions. We present a preliminary report on the use of Rasburicase plus MTX combination therapy in treating a single case of refractory tophaceous gout, highlighting potential areas for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.